IFN-γ Cancer Research Results

IFN-γ, Interferon-γ: Click to Expand ⟱
Source:
Type:
Plays a key role in activation of cellular immunity and subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro-apoptotic and antiproliferative functions, IFN-γ is considered potentially useful for adjuvant immunotherapy for different types of cancer.
Moreover, it IFN-γ may inhibit angiogenesis in tumor tissue, induce regulatory T-cell apoptosis, and/or stimulate the activity of M1 proinflammatory macrophages to overcome tumor progression.
However, the current understanding of the roles of IFN-γ in the tumor microenvironment (TME) may be misleading in terms of its clinical application.

IFN-γ is often expressed in the tumor microenvironment, particularly in response to immune cell infiltration. Its expression can be influenced by the presence of tumor-infiltrating lymphocytes (TILs) and other immune cells.
High levels of IFN-γ are typically associated with a Th1 immune response, which is generally considered beneficial for anti-tumor immunity.

Tumor Suppression:
In many cases, IFN-γ has tumor-suppressive effects, as it can inhibit tumor cell proliferation and induce apoptosis in certain cancer types.
Scientific Papers found: Click to Expand⟱
3290- SIL,    A review of therapeutic potentials of milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related patents
- Analysis, Var, NA
hepatoP↑, chemoP↑, *lipid-P↓, *antiOx↑, tumCV↓, TumCMig↓, Apoptosis↑, ROS↑, GSH↓, Bcl-2↓, survivin↓, cycD1/CCND1↓, NOTCH1↓, BAX↑, NF-kB↓, COX2↓, LOX1↓, iNOS↓, TNF-α↓, IL1↓, Inflam↓, *toxicity↓, CXCR4↓, EGFR↓, ERK↓, MMP↓, Cyt‑c↑, TumCCA↑, RB1↑, P53↑, P21↑, p27↑, cycE/CCNE↓, CDK4↓, p‑pRB↓, Hif1a↓, cMyc↓, IL1β↓, IFN-γ↓, PCNA↓, PSA↓, CYP1A1↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3648- SIL,    Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- Review, NA, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *necrosis↓, *hepatoP↑, *IL1↓, *IL6↓, *TNF-α↓, *IFN-γ↓, MAPK↓, Apoptosis↑, Cyt‑c↑, Casp3↑, Casp9↑, *PPARγ↑, *GLUT4↑, *HSPs↓, *HSP27↑, *Trx↑, *SIRT1↑, *ALAT↓, *GSH↑, *lipid-P↓, *TNF-α↓, TumCG↓, P21↑, CDK4↑,
3646- SIL,    "Silymarin", a promising pharmacological agent for treatment of diseases
- Review, NA, NA
*P-gp↓, *Inflam↓, *hepatoP↑, *antiOx↑, *GSH↑, *BioAv↑, *SOD↑, *IFN-γ↓, *IL4↓, *IL10↓, *Half-Life↓, *TNF-α↓, *ALAT↓, *AST↓, Akt↓, chemoP↑, β-catenin/ZEB1↓, TumCP↓, MMP↓, Cyt‑c↑, *RenoP↑, *BBB↑,
3314- SIL,    Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review
- Review, NA, NA
*antiOx↑, *hepatoP↑, *Half-Life↑, *ROS↓, *GSH↑, *hepatoP↑, *lipid-P↓, *TNF-α↓, *IFN-γ↓, *IL2↓, *IL4↓, *NF-kB↓, *iNOS↓, *OATPs↓, *OCT4↓, *Inflam↓, *PGE2↓, MMPs↓, VEGF↓, angioG↓, STAT3↓, *ALAT↓, *AST↓, Dose↝,
3042- SK,    The protective effects of Shikonin on lipopolysaccharide/D -galactosamine-induced acute liver injury via inhibiting MAPK and NF-kB and activating Nrf2/HO-1 signaling pathways
- in-vivo, Nor, NA
*TNF-α↓, *IL1β↓, *IL6↓, *IFN-γ↓, *ALAT↓, *AST↓, *MPO↓, *ROS↓, *JNK↓, *ERK↓, *p38↓, *NF-kB↓, *p‑IKKα↓, *SOD↑, *GSH↑, *HO-1↑, *NRF2↑, *hepatoP↑,
1049- SK,    Shikonin inhibits immune checkpoint PD-L1 expression on macrophage in sepsis by modulating PKM2
- in-vivo, NA, NA
TNF-α↓, IL6↓, IFN-γ↓, IL1β↓, PD-L1↓, p‑PKM2↓,
1195- SM,    Salvia miltiorrhiza polysaccharide activates T Lymphocytes of cancer patients through activation of TLRs mediated -MAPK and -NF-κB signaling pathways
- in-vitro, Lung, A549 - in-vitro, Liver, HepG2 - in-vitro, CRC, HCT116
T-Cell↑, TumCP∅, IL4↑, IL6↑, IFN-γ↑, TLR4↑, TLR1↑, TLR2↑, p‑JNK↑, p‑ERK↑, IKKα↑,
3563- TQ,    Thymoquinone (TQ) demonstrates its neuroprotective effect via an anti-inflammatory action on the Aβ(1–42)-infused rat model of Alzheimer's disease
- in-vivo, AD, NA
*memory↑, *IFN-γ↑, *neuroP↑, *Inflam↓, *cognitive↑,
3571- TQ,    The Role of Thymoquinone in Inflammatory Response in Chronic Diseases
- Review, Var, NA - Review, Stroke, NA
*BioAv↓, *BioAv↑, *Inflam↓, *antiOx↑, *ROS↓, *GSH↑, *GSTs↑, *MPO↓, *NF-kB↓, *COX2↓, *IL1β↓, *TNF-α↓, *IFN-γ↓, *IL6↓, *cardioP↑, *lipid-P↓, *TAC↑, *RenoP↑, Apoptosis↑, TumCCA↑, TumCP↓, TumCMig↓, angioG↓, TNF-α↓, NF-kB↓, ROS↑, EMT↓, *Aβ↓, *p‑tau↓, *BACE↓, *TLR2↓, *TLR4↓, *MyD88↓, *IRF3↓, *eff↑, eff↑, DNAdam↑, *iNOS↓,
3410- TQ,    Anti-inflammatory effects of thymoquinone and its protective effects against several diseases
- Review, Arthritis, NA
*Inflam↓, *antiOx↑, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL6↓, *TNF-α↓, *IFN-γ↓, *PGE2↓, *cardioP↑, *Catalase↑, *SOD↑, *Thiols↑, *neuroP↑, *IL12↓, *MCP1/CCL2↓, *CXCc↓, *ROS↓,
3112- VitC,    Antioxidative and Anti-Inflammatory Activity of Ascorbic Acid
- Review, Nor, NA
*ROS↓, *antiOx↑, *SOD↑, *Catalase↑, *GPx↑, *NRF2↑, *AP-1↑, *Inflam↓, *CRP↓, IFN-γ↓,

Showing Research Papers: 51 to 62 of 62
Prev Page 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 62

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

CYP1A1↓, 1,   GSH↓, 1,   GSH↑, 1,   lipid-P↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,   MMP↓, 3,   Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 2,   p‑PKM2↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 3,   BAX↑, 2,   Bcl-2↓, 2,   Bcl-xL↓, 1,   BIM↓, 1,   Casp↑, 1,   Casp3↑, 2,   Casp9↑, 1,   Cyt‑c↑, 4,   iNOS↓, 1,   p‑JNK↑, 1,   MAPK↓, 2,   p27↑, 1,   survivin↓, 2,   YAP/TEAD↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

HATs↑, 1,   p‑pRB↓, 1,   tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 2,   PCNA↓, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   CDK4↑, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   P21↑, 2,   RB1↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 2,   ERK↓, 2,   p‑ERK↑, 1,   HDAC↓, 1,   mTOR↓, 1,   NOTCH1↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

CD31↓, 1,   MMPs↓, 2,   TumCMig↓, 2,   TumCP↓, 2,   TumCP∅, 1,   TumMeta↓, 1,   uPA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   EGFR↓, 1,   Hif1a↓, 2,   LOX1↓, 1,   VEGF↓, 2,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   CXCR4↓, 1,   IFN-γ↓, 3,   IFN-γ↑, 2,   IKKα↑, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 2,   IL2↑, 1,   IL4↑, 1,   IL6↓, 1,   IL6↑, 1,   Inflam↓, 2,   MDSCs↓, 1,   NF-kB↓, 2,   PD-L1↓, 1,   PSA↓, 1,   T-Cell↑, 1,   TLR1↑, 1,   TLR2↑, 1,   TLR4↑, 1,   TNF-α↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   IL6↓, 1,   IL6↑, 1,   PD-L1↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   chemoP↑, 3,   hepatoP↑, 2,   neuroP↑, 1,  
Total Targets: 97

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 7,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 5,   GSTs↑, 1,   HO-1↑, 2,   lipid-P↓, 5,   MPO↓, 2,   NRF2↑, 3,   ROS↓, 5,   SOD↑, 4,   TAC↑, 1,   Thiols↑, 1,   Trx↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 4,   PPARγ↑, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 2,   JNK↓, 1,   necrosis↓, 1,   p38↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP27↑, 1,   HSPs↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   OCT4↓, 1,  

Migration(tgid=13) ⓘ

AP-1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT4↑, 1,   OATPs↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   CRP↓, 1,   CXCc↓, 1,   IFN-γ↓, 6,   IFN-γ↑, 1,   p‑IKKα↓, 1,   IL1↓, 1,   IL10↓, 1,   IL12↓, 1,   IL1β↓, 3,   IL2↓, 1,   IL4↓, 2,   IL6↓, 4,   Inflam↓, 7,   MCP1/CCL2↓, 1,   MyD88↓, 1,   NF-kB↓, 3,   PGE2↓, 2,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 7,  

Synaptic & Neurotransmission(tgid=18) ⓘ

p‑tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 2,   eff↑, 1,   Half-Life↓, 1,   Half-Life↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 4,   AST↓, 3,   CRP↓, 1,   IL6↓, 4,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 2,   cognitive↑, 1,   hepatoP↑, 5,   memory↑, 1,   neuroP↑, 2,   RenoP↑, 2,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

IRF3↓, 1,  
Total Targets: 71

Scientific Paper Hit Count for: IFN-γ, Interferon-γ
6 Silymarin (Milk Thistle) silibinin
4 immunotherapy
3 Quercetin
3 Thymoquinone
2 Astaxanthin
2 chitosan
2 Curcumin
2 Docosahexaenoic Acid
2 Emodin
2 Luteolin
2 Lycopene
2 Magnetic Field Rotating
2 Magnetic Fields
2 Sulforaphane (mainly Broccoli)
2 Shikonin
1 Astragalus
1 5-fluorouracil
1 alpha Linolenic acid
1 beta-glucans
1 Berberine
1 Betulinic acid
1 Bifidobacterium
1 Bromelain
1 Boron
1 Butyrate
1 Caffeine
1 Capsaicin
1 Carvacrol
1 Chrysin
1 Copper and Cu NanoParticles
1 Chemotherapy
1 diet Fermented Foods
1 diet FMD Fasting Mimicking Diet
1 Electrical Pulses
1 eicosapentaenoic acid
1 Gallic acid
1 Germanium Organic/Ge-132 / propagermanium (organogermanium)
1 Ginger/6-Shogaol/Gingerol
1 Hydrogen Gas
1 Honokiol
1 Rapamycin
1 Bicarbonate(Sodium)
1 Nimbolide
1 Propolis -bee glue
1 Piperine
1 Selenium
1 Salvia miltiorrhiza
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:442  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page